Citius Pharmaceuticals Stock News

CRANFORD, N.J. , April 14, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commerc

Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lymphoma.

Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lymphoma.

Here's what you need to know about trading penny stocks on April 6th The post Trading Penny Stocks on April 6th, MOBQ Stock Pushes Up appeared first on Penny Stocks to Buy, Picks, News and Information

Here's what you need to know about trading penny stocks on April 6th The post Trading Penny Stocks on April 6th, MOBQ Stock Pushes Up appeared first on Penny Stocks to Buy, Picks, News and Information

Shares of Citius Pharmaceuticals Inc. CTXR, -1.60% were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from a Phase 3 clinical trial for its experimental tre

5 Active Programs With Near Term Catalysts.

Check these three biotech penny stocks out for your watchlist The post Top Biotech Penny Stocks to Buy Now? 3 to Watch in March  appeared first on Penny Stocks to Buy, Picks, News and Information | P

CRANFORD, N.J., March 3, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercia

Biotech penny stocks to watch as Ukraine-Russia conflict builds steam. The post Biotech Penny Stocks To Buy For Under $5 As Russia Ukraine Conflict Heats Up appeared first on Penny Stocks to Buy, Pick

Biotech penny stocks to watch as Ukraine-Russia conflict builds steam. The post Biotech Penny Stocks To Buy For Under $5 As Russia Ukraine Conflict Heats Up appeared first on Penny Stocks to Buy, Pick

The FDA has issued a Study May Proceed letter for Citius Pharmaceuticals Inc''s (NASDAQ: CTXR ) Halo-Lido to treat hemorrhoids. The Company anticipates initiating a Phase 2b study in 1H of 2022. Halo-Lido is a proprietary topical formulation of halobetasol and lidocaine intended to provide symptomatic relief to individuals … Full story available on Benzinga.com

NEW YORK , Feb. 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORPH, YELP, DCFC, BLDE, and CTXR. … Full story available on Benzinga.com

Citius Pharmaceuticals press release (CTXR): FQ1 GAAP EPS of -$0.06 in-line.Cash and cash equivalents of $65.4M."We anticipate 2022 will be a year of important catalysts for Citius

CRANFORD, N.J. , Feb. 10, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR ), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today reported business and financial results for the first fiscal quarter of 2022 ended December 31, 2021 . Fiscal Q1 2022 Business Highlights and Subsequent Developments Pivotal Phase 3 trial of I/ONTAK (E7777) completed in December 2021 with topline results anticipated in the first half of 2022 and a biologics license application (BLA) submission planned in the second half of 2022; Mino-Lok ® Phase 3 trial completion anticipated in 2022; and, Regulatory, manufacturing, clinical and commercial capabilities expanded to support late-stage pipeline with the addition of seasoned executives with extensive pharmaceutical industry experience: Catherine Kessler MS – EVP, Regulatory Affairs Kelly Creighton , PhD – EVP, Chemistry, Manufacturing and Controls Kevin Carey – VP, Program Management Preeti Singh , MD – Medical Director Financial Highlights Cash and cash equivalents of $65.